Tuberculosis and Respiratory Diseases

  • 제87권1호
  • /
  • Pages.22-30
  • /
  • 2024
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

Immune Evasion of G-CSF and GM-CSF in Lung Cancer

  • Yeonhee Park (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Chaeuk Chung (Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Chungnam National University College of Medicine)
  • 투고 : 2023.03.23
  • 심사 : 2023.09.12
  • 발행 : 2024.01.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Tumor immune evasion is a complex process that involves various mechanisms, such as antigen recognition restriction, immune system suppression, and T cell exhaustion. The tumor microenvironment contains various immune cells involved in immune evasion. Recent studies have demonstrated that granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) induce immune evasion in lung cancer by modulating neutrophils and myeloid-derived suppressor cells. Here we describe the origin and function of G-CSF and GM-CSF, particularly their role in immune evasion in lung cancer. In addition, their effects on programmed death-ligand 1 expression and clinical implications are discussed.

키워드

과제정보

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT) (No. NRF-2017R1A5A2015385, NRF2022R1A2C2010148) and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Korea (grant number: HR20C0025).

참고문헌

  1. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24:207-12. https://doi.org/10.1016/j.coi.2011.12.009
  2. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-77. https://doi.org/10.1038/nri2326
  3. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800. https://doi.org/10.1038/nm730
  4. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012;21:822-35. https://doi.org/10.1016/j.ccr.2012.04.025
  5. Bharadwaj U, Li M, Zhang R, Chen C, Yao Q. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res 2007;67:5479-88. https://doi.org/10.1158/0008-5472.CAN-06-3963
  6. Tang D, Zhang D, Heng Y, Zhu XK, Lin HQ, Zhou J, et al. Tumor-infiltrating PD-L1+ neutrophils induced by GMCSF suppress T cell function in laryngeal squamous cell carcinoma and predict unfavorable prognosis. J Inflamm Res 2022;15:1079-97.
  7. He K, Liu X, Hoffman RD, Shi RZ, Lv GY, Gao JL. G-CSF/GM-CSF-induced hematopoietic dysregulation in the progression of solid tumors. FEBS Open Bio 2022;12:1268-85. https://doi.org/10.1002/2211-5463.13445
  8. Zhang X, Xu W. Neutrophils diminish T-cell immunity to foster gastric cancer progression: the role of GM-CSF/PD-L1/PD-1 signalling pathway. Gut 2017;66:1878-80. https://doi.org/10.1136/gutjnl-2017-313923
  9. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010;40:22-35. https://doi.org/10.1002/eji.200939903
  10. Rong QX, Wang F, Guo ZX, Hu Y, An SN, Luo M, et al. GMCSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma. Mol Cancer 2021;20:80.
  11. Gutschalk CM, Herold-Mende CC, Fusenig NE, Mueller MM. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res 2006;66:8026-36. https://doi.org/10.1158/0008-5472.CAN-06-0158
  12. Katsumata N, Eguchi K, Fukuda M, Yamamoto N, Ohe Y, Oshita F, et al. Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res 1996;2:553-9.
  13. Braun B, Lange M, Oeckler R, Mueller MM. Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization. J Neurooncol 2004;68:131-40. https://doi.org/10.1023/B:NEON.0000027751.87894.f0
  14. Thorn M, Guha P, Cunetta M, Espat NJ, Miller G, Junghans RP, et al. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases. Cancer Gene Ther 2016;23:188-98. https://doi.org/10.1038/cgt.2016.19
  15. Wang TT, Zhao YL, Peng LS, Chen N, Chen W, Lv YP, et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut 2017;66:1900-11. https://doi.org/10.1136/gutjnl-2016-313075
  16. Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in neutropenia. J Immunol 2015;195:1341-9. https://doi.org/10.4049/jimmunol.1500861
  17. Hong IS. Stimulatory versus suppressive effects of GMCSF on tumor progression in multiple cancer types. Exp Mol Med 2016;48:e242.
  18. Eyles JL, Hickey MJ, Norman MU, Croker BA, Roberts AW, Drake SF, et al. A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. Blood 2008;112:5193-201. https://doi.org/10.1182/blood-2008-02-139535
  19. Pei XH, Nakanishi Y, Takayama K, Bai F, Hara N. Granu-locyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br J Cancer 1999;79:40-6. https://doi.org/10.1038/sj.bjc.6690009
  20. Casbon AJ, Reynaud D, Park C, Khuc E, Gan DD, Schepers K, et al. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc Natl Acad Sci U S A 2015;112:E566-75. https://doi.org/10.1073/pnas.1424927112
  21. Masucci MT, Minopoli M, Carriero MV. Tumor associated neutrophils: their role in tumorigenesis, metastasis, prognosis and therapy. Front Oncol 2019;9:1146.
  22. Kuijpers T. Structure and composition of neutrophils, eosinophils, and basophils. In: Kaushansky K, Prchal JT, Burns LJ, Lichtman MA, Levi M, Linch DC, editors. Williams hematology. 10th ed. New York: McGraw-Hill Education; 2021 [cited 2023 Sep 22]. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2962§ionid=252530906.
  23. Silvestre-Roig C, Hidalgo A, Soehnlein O. Neutrophil heterogeneity: implications for homeostasis and pathogenesis. Blood 2016;127:2173-81. https://doi.org/10.1182/blood-2016-01-688887
  24. Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One 2011;6:e27690.
  25. Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol 2012;91:167-81. https://doi.org/10.1189/jlb.0311177
  26. Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, et al. LXR/ApoE activation restricts innate immune suppression in cancer. Cell 2018;172:825-40. https://doi.org/10.1016/j.cell.2017.12.026
  27. Komura N, Mabuchi S, Shimura K, Yokoi E, Kozasa K, Kuroda H, et al. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer. Cancer Immunol Immunother 2020;69:2477-99. https://doi.org/10.1007/s00262-020-02628-2
  28. Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol 2019;12:76.
  29. Pan Y, Yu Y, Wang X, Zhang T. Tumor-associated macrophages in tumor immunity. Front Immunol 2020;11:583084.
  30. Jesser EA, Brady NJ, Huggins DN, Witschen PM, O'Connor CH, Schwertfeger KL. STAT5 is activated in macrophages by breast cancer cell-derived factors and regulates macrophage function in the tumor microenvironment. Breast Cancer Res 2021;23:104.
  31. Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, et al. Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Cell Rep 2018;23:3946-59. https://doi.org/10.1016/j.celrep.2018.05.082
  32. Beauvillain C, Delneste Y, Scotet M, Peres A, Gascan H, Guermonprez P, et al. Neutrophils efficiently cross-prime naive T cells in vivo. Blood 2007;110:2965-73. https://doi.org/10.1182/blood-2006-12-063826
  33. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009;16:183-94. https://doi.org/10.1016/j.ccr.2009.06.017
  34. Gershkovitz M, Caspi Y, Fainsod-Levi T, Katz B, Michaeli J, Khawaled S, et al. TRPM2 mediates neutrophil killing of disseminated tumor cells. Cancer Res 2018;78:2680-90. https://doi.org/10.1158/0008-5472.CAN-17-3614
  35. Park J, Wysocki RW, Amoozgar Z, Maiorino L, Fein MR, Jorns J, et al. Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci Transl Med 2016;8:361ra138.
  36. Das A, Monteiro M, Barai A, Kumar S, Sen S. MMP proteolytic activity regulates cancer invasiveness by modulating integrins. Sci Rep 2017;7:14219.
  37. Mishalian I, Bayuh R, Eruslanov E, Michaeli J, Levy L, Zolotarov L, et al. Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17: a new mechanism of impaired antitumor immunity. Int J Cancer 2014;135:1178-86. https://doi.org/10.1002/ijc.28770
  38. Shen L, Smith JM, Shen Z, Eriksson M, Sentman C, Wira CR. Inhibition of human neutrophil degranulation by transforming growth factor-beta1. Clin Exp Immunol 2007;149:155-61. https://doi.org/10.1111/j.1365-2249.2007.03376.x
  39. Saha S, Biswas SK. Tumor-associated neutrophils show phenotypic and functional divergence in human lung cancer. Cancer Cell 2016;30:11-3. https://doi.org/10.1016/j.ccell.2016.06.016
  40. Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 2010;120:1151-64. https://doi.org/10.1172/JCI37223
  41. Andzinski L, Kasnitz N, Stahnke S, Wu CF, Gereke M, von Kockritz-Blickwede M, et al. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer 2016;138:1982-93. https://doi.org/10.1002/ijc.29945
  42. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-5. https://doi.org/10.1126/science.1092385
  43. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol 2018;18:134-47. https://doi.org/10.1038/nri.2017.105
  44. He M, Peng A, Huang XZ, Shi DC, Wang JC, Zhao Q, et al. Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma. Oncoimmunology 2016;5:e1219828.
  45. Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007;450:825-31. https://doi.org/10.1038/nature06348
  46. Phan VT, Wu X, Cheng JH, Sheng RX, Chung AS, Zhuang G, et al. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A 2013;110:6079-84. https://doi.org/10.1073/pnas.1303302110
  47. Yokoi E, Mabuchi S, Komura N, Shimura K, Kuroda H, Kozasa K, et al. The role of myeloid-derived suppressor cells in endometrial cancer displaying systemic inflammatory response: clinical and preclinical investigations. Oncoimmunology 2019;8:e1662708.
  48. Sasano T, Mabuchi S, Kozasa K, Kuroda H, Kawano M, Takahashi R, et al. The highly metastatic nature of uterine cervical/endometrial cancer displaying tumor-related leukocytosis: clinical and preclinical investigations. Clin Cancer Res 2018;24:4018-29. https://doi.org/10.1158/1078-0432.CCR-17-2472
  49. Kawano M, Mabuchi S, Matsumoto Y, Sasano T, Takahashi R, Kuroda H, et al. The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer. Sci Rep 2015;5:18217.
  50. Mouchemore KA, Anderson RL, Hamilton JA. Neutrophils, G-CSF and their contribution to breast cancer metastasis. FEBS J 2018;285:665-79. https://doi.org/10.1111/febs.14206
  51. Shen X, Zhang L, Li J, Li Y, Wang Y, Xu ZX. Recent findings in the regulation of programmed death ligand 1 expression. Front Immunol 2019;10:1337.
  52. Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer 2019;18:10.
  53. Arasanz H, Gato-Canas M, Zuazo M, Ibanez-Vea M, Breckpot K, Kochan G, et al. PD1 signal transduction pathways in T cells. Oncotarget 2017;8:51936-45. https://doi.org/10.18632/oncotarget.17232
  54. Shinchi Y, Ishizuka S, Komohara Y, Matsubara E, Mito R, Pan C, et al. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma. Cancer Immunol Immunother 2022;71:2645-61. https://doi.org/10.1007/s00262-022-03187-4
  55. Gato-Canas M, Zuazo M, Arasanz H, Ibanez-Vea M, Lorenzo L, Fernandez-Hinojal G, et al. PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell Rep 2017;20:1818-29. https://doi.org/10.1016/j.celrep.2017.07.075
  56. Gupta HB, Clark CA, Yuan B, Sareddy G, Pandeswara S, Padron AS, et al. Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduct Target Ther 2016;1:16030.
  57. Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res 2016;76:6964-74. https://doi.org/10.1158/0008-5472.CAN-16-0258
  58. Gao Y, Nihira NT, Bu X, Chu C, Zhang J, Kolodziejczyk A, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol 2020;22:1064-75. https://doi.org/10.1038/s41556-020-0562-4
  59. Miyazawa A, Ito S, Asano S, Tanaka I, Sato M, Kondo M, et al. Regulation of PD-L1 expression by matrix stiffness in lung cancer cells. Biochem Biophys Res Commun 2018;495:2344-9. https://doi.org/10.1016/j.bbrc.2017.12.115
  60. Plenz G, Reichenberg S, Koenig C, Rauterberg J, Deng MC, Baba HA, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) modulates the expression of type VIII collagen mRNA in vascular smooth muscle cells and both are codistributed during atherogenesis. Arterioscler Thromb Vasc Biol 1999;19:1658-68. https://doi.org/10.1161/01.ATV.19.7.1658
  61. Gaynor RB. A role for extracellular matrix binding receptors in regulating hematopoietic growth factor signaling. Proc Natl Acad Sci U S A 2003;100:13737-8. https://doi.org/10.1073/pnas.2536856100
  62. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70. https://doi.org/10.1056/NEJM199107183250305
  63. Fan Z, Li Y, Zhao Q, Fan L, Tan B, Zuo J, et al. Highly expressed granulocyte colony-stimulating factor (G-CSF) and granulocyte colony-stimulating factor receptor (G-CSFR) in human gastric cancer leads to poor survival. Med Sci Monit 2018;24:1701-11. https://doi.org/10.12659/MSM.909128
  64. Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, Petrescu D, et al. Cytokine patterns in brain tumour progression. Mediators Inflamm 2013;2013:979748.
  65. Mroczko B, Szmitkowski M, Niklinski J. Stem cell factor and granulocyte-macrophage-colony stimulating factor as candidates for tumour markers for non-small-cell lung cancer. Clin Chem Lab Med 1999;37:959-62. https://doi.org/10.1515/CCLM.1999.141
  66. Stathopoulos GP, Armakolas A, Tranga T, Marinou H, Stathopoulos J, Chandrinou H. Granulocyte colony-stimulating factor expression as a prognostic biomarker in non-small cell lung cancer. Oncol Rep 2011;25:1541-4. https://doi.org/10.3892/or.2011.1226
  67. Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A 2010;107:21248-55.  https://doi.org/10.1073/pnas.1015855107